Patents by Inventor Krishnan Nandabalan

Krishnan Nandabalan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250206714
    Abstract: The disclosure pertains to chemical entities such as a compound or a pharmaceutically acceptable salt that inhibit inflammatory responses by, for example, inhibiting the oligomerization of Apoptosis-associated speck-like protein containing a C-terminal caspase-recruitment domain (ASC). Also provided are methods of treating various disease states using compounds that inhibit oligomerization of ASC protein.
    Type: Application
    Filed: March 11, 2025
    Publication date: June 26, 2025
    Inventors: Krishnan Nandabalan, Sameer Sharma, Matthew Sternke, Praful Gupta, Govindan Vijayadamodar, Madan Anant, Raghava Reddy Kethiri, Krishna Reddy Gankidi
  • Publication number: 20250099430
    Abstract: There is provided a composition suitable for oral transmucosal administration (sublingual) comprising dexmedetomidine. The composition is useful for the treatment of sleep disorders such as insomnia and capable of providing sleep on demand. The composition comprises an effective amount of dexmedetomidine or pharmaceutically acceptable salts thereof, solvates thereof, or derivatives thereof, formulated for delivery of dexmedetomidine across a subject's oral mucosa.
    Type: Application
    Filed: April 12, 2024
    Publication date: March 27, 2025
    Inventors: Harsh NEGI, Deepa SAINI, Sameer SHARMA, Krishnan NANDABALAN, Frank YOCCA
  • Publication number: 20240252470
    Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses die sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
    Type: Application
    Filed: February 8, 2024
    Publication date: August 1, 2024
    Inventors: Krishnan NANDABALAN, Frank YOCCA, Sameer SHARMA, Harsh NEGI, Deepa SAINI
  • Patent number: 11931340
    Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: March 19, 2024
    Assignee: BioXcel Therapeutics, Inc.
    Inventors: Krishnan Nandabalan, Frank Yocca, Sameer Sharma, Harsh Negi, Deepa Saini
  • Publication number: 20230414572
    Abstract: There is provided a composition suitable for oral transmucosal administration (sublingual) comprising dexmedetomidine. The composition is useful for the treatment of sleep disorders such as insomnia and capable of providing sleep on demand. The composition comprises an effective amount of dexmedetomidine or pharmaceutically acceptable salts thereof, solvates thereof, or derivatives thereof, formulated for delivery of dexmedetomidine across a subject's oral mucosa.
    Type: Application
    Filed: September 5, 2023
    Publication date: December 28, 2023
    Applicant: BioXcel Therapeutics, Inc.
    Inventors: Harsh NEGI, Deepa SAINI, Sameer SHARMA, Krishnan NANDABALAN, Frank YOCCA
  • Publication number: 20230398124
    Abstract: The present disclosure relates to uses of compounds of formula (I) in treating or preventing variety of diseases, or conditions in a subject particularly hepatobiliary disease, gastrointestinal diseases associated with hepatobiliary disease and/or eosinophilic diseases using therapeutic effective amounts of compound of general formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein the variables R1, R2, Ar, X, Z and W have the meaning as described herein.
    Type: Application
    Filed: June 9, 2023
    Publication date: December 14, 2023
    Inventors: Krishnan Nandabalan, Sameer Sharma
  • Patent number: 11839604
    Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: December 12, 2023
    Assignee: Bioxcel Therapeutics, Inc.
    Inventors: Krishnan Nandabalan, Frank Yocca, Sameer Sharma, Harsh Negi, Deepa Saini
  • Patent number: 11786508
    Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
    Type: Grant
    Filed: November 18, 2022
    Date of Patent: October 17, 2023
    Assignee: BioXcel Therapeutics, Inc.
    Inventors: Krishnan Nandabalan, Frank Yocca, Sameer Sharma, Harsh Negi, Deepa Saini
  • Publication number: 20230227918
    Abstract: The present invention generally relates to a method of diagnosing, prognosing and treating prostate cancer patients. Particularly, the present invention relates to a method of selecting patients with castration resistant prostate cancer (CrPC) for combination therapy comprising a selective dipeptidyl peptidase inhibitor and a PD-1 axis antagonist. The present invention provides a computational approach to identifying potential patients for CrPC. The present invention also relates to a method of treating castration resistant prostate cancer (CrPC) patients with said combination therapy.
    Type: Application
    Filed: January 20, 2023
    Publication date: July 20, 2023
    Inventors: Krishnan NANDABALAN, Luca RASTELLI
  • Publication number: 20230218580
    Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
    Type: Application
    Filed: March 22, 2023
    Publication date: July 13, 2023
    Inventors: Krishnan NANDABALAN, Frank YOCCA, Sameer SHARMA, Harsh NEGI, Deepa SAINI
  • Patent number: 11613785
    Abstract: The present invention generally relates to a method of diagnosing, prognosing and treating prostate cancer patients. Particularly, the present invention relates to a method of selecting patients with castration resistant prostate cancer (CrPC) for combination therapy comprising a selective dipeptidyl peptidase inhibitor and a PD-1 axis antagonist. The present invention provides a computational approach to identifying potential patients for CrPC. The present invention also relates to a method of treating castration resistant prostate cancer (CrPC) patients with said combination therapy.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: March 28, 2023
    Assignee: OnkosXcel Therapeutics, LLC
    Inventors: Krishnan Nandabalan, Luca Rastelli
  • Publication number: 20230093109
    Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
    Type: Application
    Filed: November 18, 2022
    Publication date: March 23, 2023
    Inventors: Krishnan NANDABALAN, Frank YOCCA, Sameer SHARMA, Harsh NEGI, Deepa SAINI
  • Publication number: 20230081503
    Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
    Type: Application
    Filed: November 18, 2022
    Publication date: March 16, 2023
    Inventors: Krishnan NANDABALAN, Frank YOCCA, Sameer SHARMA, Harsh NEGI, Deepa SAINI
  • Publication number: 20220031663
    Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
    Type: Application
    Filed: October 7, 2021
    Publication date: February 3, 2022
    Inventors: Krishnan NANDABALAN, Frank YOCCA, Sameer SHARMA
  • Publication number: 20210355541
    Abstract: The present invention generally relates to a method of diagnosing, prognosing and treating prostate cancer patients. Particularly, the present invention relates to a method of selecting patients with castration resistant prostate cancer (CrPC) for combination therapy comprising a selective dipeptidyl peptidase inhibitor and a PD-1 axis antagonist. The present invention provides a computational approach to identifying potential patients for CrPC. The present invention also relates to a method of treating castration resistant prostate cancer (CrPC) patients with said combination therapy.
    Type: Application
    Filed: January 9, 2018
    Publication date: November 18, 2021
    Inventors: Krishnan NANDABALAN, Luca RASTELLI
  • Publication number: 20200317784
    Abstract: Provided herein are combination methods and compositions for cancer therapies. The combinations modify multiple arms of the immune system, including an innate immunity modifier, an immune checkpoint inhibitor and a T-cell stimulator, to treat cancer.
    Type: Application
    Filed: November 13, 2018
    Publication date: October 8, 2020
    Inventors: Krishnan NANDABALAN, Vimal D. MEHTA, Luca RASTELLI, John MACDOUGALL, Jonathan ZALEVSKY, Deborah H. CHARYCH
  • Patent number: 10610563
    Abstract: The invention discloses a method of treating, preventing or ameliorating tumor or symptoms resulting from defective neurofibromatosis type-2 gene in a subject by administering to the subject a therapeutically effective amount of a ubiquitin-proteasome system inhibitor which inhibits or slows the growth of neurofibromatosis type-2-deficient tumor or associated symptoms. The invention also includes methods of diagnosis and screening of patients for neurofibromatosis type-2 and mesothelioma.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: April 7, 2020
    Assignee: BIOXCEL CORPORATION
    Inventors: Krishnan Nandabalan, Sameer Sharma, Luca Rastelli
  • Patent number: 10572631
    Abstract: A method, non-transitory computer readable medium, and pharmaceutical assessment computing device that effectively reformulates and repositions pharmaceutical molecule data. With this technology, therapeutic area data comprising a medical condition and pharmaceutical molecule data corresponding to the medical condition is obtained. The pharmaceutical molecule data comprises pharmaceutical molecule identifiers and usage data parameters with corresponding usage data values for each of the pharmaceutical molecule identifiers. Each of the usage data values is compared to a corresponding usage threshold value. Reformulation opportunities are determined for each of the pharmaceutical molecule identifiers comprising a usage data value that exceeds the corresponding usage threshold value.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: February 25, 2020
    Assignee: BIOXCEL CORPORATION
    Inventors: Krishnan Nandabalan, Vimal Mehta, Ramkesh Meena
  • Publication number: 20190365715
    Abstract: The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and/or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.
    Type: Application
    Filed: December 29, 2017
    Publication date: December 5, 2019
    Inventors: Krishnan NANDABALAN, Frank YOCCA, Sameer SHARMA
  • Publication number: 20190298720
    Abstract: The present disclosure provides methods and compositions for the use of a Src family kinase (SFK) inhibitor for the treatment of anemia associated with ribosomal disorders, such as diamond blackfan anemia.
    Type: Application
    Filed: June 9, 2017
    Publication date: October 3, 2019
    Inventor: Krishnan NANDABALAN